Ultimovacs ASA (OSL:ULTI) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Dividend Payout Ratio?

Ultimovacs ASA's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Ultimovacs ASA's Dividend Payout Ratio or its related term are showing as below:

OSL:ULTI's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.415
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-30), the Dividend Yield % of Ultimovacs ASA is 0.00%.

Ultimovacs ASA's Dividends per Share for the months ended in Dec. 2023 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Ultimovacs ASA Dividend Payout Ratio Historical Data

The historical data trend for Ultimovacs ASA's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Dividend Payout Ratio Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Ultimovacs ASA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ultimovacs ASA's Dividend Payout Ratio

For the Biotechnology subindustry, Ultimovacs ASA's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultimovacs ASA's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Dividend Payout Ratio falls into.

Ultimovacs ASA Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Ultimovacs ASA's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-5.87
	=	N/A

Ultimovacs ASA's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-1.6
	=	N/A

Ultimovacs ASA (OSL:ULTI) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Ultimovacs ASA Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.